Skip to main content
. Author manuscript; available in PMC: 2023 Mar 1.
Published in final edited form as: Adv Chronic Kidney Dis. 2022 Mar;29(2):188–200.e1. doi: 10.1053/j.ackd.2021.09.002

Figure 1.

Figure 1.

CAR-T therapy in patient with kidney transplants. Immunosuppression agents need to be minimized 2-3 weeks before leukapheresis (1), to ensure the efficacy of CAR-T manufacturing (2). Lymphodepleting chemotherapy (3) will be administered 3-5 days before CAR-T infusion (4). Risk of acute kidney injury (AKI) and rejection is high during peri-infusion period, along with cytokine release syndrome (CRS). Anti-IL-6 treatment can be used for treatment of CRS.